The latest ceremony will include a new award for Medical Technology
September, 2017, London: Entries have opened for the 2018 UK Prix Galien Awards, the highest accolade for innovation in life sciences.
The 2018 Awards will include an exciting new category for Medical Technology, alongside accolades for Innovative Products, Orphan Products and Real World Evidence.
The Real World Evidence prize was introduced at the previous UK Prix Galien in 2016, making it the first award in the world to recognise excellence in this important area of medicine. The inaugural RWE award was open to past winners and commended products. In 2018, the category is open to all medicines licensed for use in UK in the past five years.
The process culminates in an illustrious ceremony at the House of Commons on 26th September 2018.
Prix Galien, established in 1970, celebrates outstanding efforts to improve the human condition through the development of novel, high-value medical innovations. It is recognised in 17 countries across Europe and North America, with presence in emerging markets in Asia and Latin America expected soon.
The Awards have been acclaimed by Nobel Laureates as a Nobel Prize for biomedical innovation – and praised for their prestige and purpose by political heavyweights such as Obama, Clinton, Blair and Ban Ki Moon. Moreover, they are independently judged by a panel of healthcare leaders and luminaries, maintaining the highest standards of scientific rigour. The 2018 UK judging panel is once again led by Professor Sir Michael Rawlins, Chair of MHRA and founding Chair of NICE from 1999 to 2014. The panel will be bolstered by the addition of Professor Bruce Campbell, a past Chair of NICE’s Medical Technologies Advisory Committee and its Interventional Procedures Advisory Committee. Professor Campbell’s wealth of experience in HTA and medical technologies will bring invaluable insight to judging of the Medical Technology Award.
Previous UK Prix Galien winners include well-known brands such as Viagra, Herceptin, Glivec, Xolair, Cervarix and Gardasil. More recent winners, such as Xarelto, Incivo and Victrelis, underline how pharmaceutical innovation is helping to transform healthcare services and improve public health.
In 2016, the Innovative Product Award was won by Entresto, Novartis’ breakthrough heart failure treatment. Chiesi’s Holoclar, the first stem cell therapy to receive European marketing approval, won the Orphan Product Award. The inaugural Real World Evidence Award was won by Dificlir, Astellas’ treatment for clostridium difficile infection.
With entry for the 2018 Awards now open, pharmaceutical companies are invited to put themselves in with a chance of joining the select UK Prix Galien Hall of Fame. Entrants will certainly be in good company.
Entering the 2018 Awards
Judges will be looking for innovations that demonstrate the most significant overall contribution to patient care in the UK in terms of clinical effectiveness, cost effectiveness and innovation.
The Innovative Products and Orphan Products Awards are open to products launched or granted a new indication in the UK market during the period 1st January 2016 to 29th March 2018.
The Real World Evidence Award is open to all medicines that have been licensed for use in the UK in the past five years. It will recognise excellence in the generation, collection and application of observational data to demonstrate health outcomes, real-world patient benefits or socio-economic gains.
The Medical Technology Award is open to any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination together with any accessories, including software used specifically for diagnostic and/or therapeutic purposes. Products granted a CE mark within a five-year qualifying period are eligible for entry.
Registration for entries for the 2018 Awards will close on 31st January 2018 – with final submissions due by 29th March 2018. For further details on the entry process visit www.prixgalien.co.uk and download the Entry Brochure.